| Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
|
Pediatric Blood & Cancer |
Aplastic Anemia |
| Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
|
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
| Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
|
Blood |
Aplastic Anemia |
| Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
